Frontiers in Immunology Publishes Pre-Clinical Study of Palatin’s Oral Formulation of PL8177 Demonstrating Therapeutic Effects in Inflammatory Bowel Disease

Oral PL8177 is gut restricted in rats, dogs and humans Bioinformatics data shows positive effects on enterocytes and infiltrating immune cells CRANBURY, N.J., March 2, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing…

Leave a Reply

Your email address will not be published. Required fields are marked *